Adrestia Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Proteros and Adrestia Initiate Multi-Target Partnership to Discover First-In-Class Drugs for Intractable Genetic Diseases

Details:

The partnership brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with Adrestia’s expertise in target biology with a novel synthetic rescue drug development platform.

Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Recipient: Proteros

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership October 25, 2022

ASK
US

Upload
your Marketing & Sales content

Adrestia Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration for Five Projects

Details:

The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.

Lead Product(s): Undisclosed

Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Undisclosed

Partner/Sponsor/Collaborator: GSK

Deal Size: $1,150.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 18, 2020

ASK
US

Upload
your Marketing & Sales content